孕11-13周母体因素与生物标志物筛查子痫前期
本研究基于三项前瞻性非干预筛查研究共61174例单胎妊娠,用贝叶斯定理结合母体因素与MAP、UtA-PI、PlGF、PAPP-A的MoM值预测子痫前期。在10%筛查阳性率下,联合筛查可预测90%早发型、75%早产型和41%足月型子痫前期;加入PAPP-A未改善筛查性能,筛查性能因种族起源而异。
要点
- 孕11-13周联合母体因素、MAP、UtA-PI和PlGF筛查,10%筛查阳性率下可预测90%早发型子痫前期。
- 加入PAPP-A未改善筛查性能,PAPP-A与PlGF的MoM值在子痫前期妊娠中降低。
- 筛查性能因种族起源而异,非洲-加勒比裔女性的筛查阳性率高于白人女性。
核心结论
- 孕11-13周母体因素与生物标志物联合筛查可识别高比例的早发型和早产型子痫前期妊娠。
研究设计与样本
- 数据来自三项既往报道的前瞻性非干预筛查研究,孕11+0至13+6周,共61174例单胎妊娠,其中1770例(2.9%)发生子痫前期;采用贝叶斯定理结合母体特征获得的分娩孕周先验分布与各生物标志物MoM值组合,推算个体化风险。
关键影像表现/征象
- 子痫前期妊娠与无子痫前期妊娠相比,UtA-PI和MAP的MoM值升高,PAPP-A和PlGF的MoM值降低。
- 四种生物标志物偏离正常的程度在早发型子痫前期均大于晚发型。
诊断标准与关键数值
- 母体因素、UtA-PI、MAP和PlGF联合筛查在10%筛查阳性率下预测90%早发型子痫前期、75%早产型子痫前期和41%足月型子痫前期。
- 白人女性采用母体因素、MAP、UtA-PI和PlGF联合筛查、以37周前子痫前期风险1/100为切点时,筛查阳性率10%,早发型、早产型和足月型子痫前期检出率分别为88%、69%和40%。
- 非洲-加勒比裔女性采用相同筛查方法和风险切点时,筛查阳性率34%,早发型、早产型和足月型子痫前期检出率分别为100%、92%和75%。
临床应用与阅片要点
- 孕11-13周可基于母体因素联合MAP、UtA-PI和PlGF计算个体化子痫前期风险,用于筛查早发型和早产型子痫前期。
- 筛查性能因种族起源不同,解读风险时需考虑种族背景对筛查阳性率和检出率的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To examine the performance of screening for early, preterm and term pre-eclampsia (PE) at 11-13 weeks' gestation by maternal factors and combinations of mean arterial pressure (MAP), uterine artery (UtA) pulsatility index (PI), serum placental growth factor (PlGF) and serum pregnancy-associated plasma protein-A (PAPP-A).
METHODS: The data for this study were derived from three previously reported prospective non-intervention screening studies at 11 + 0 to 13 + 6 weeks' gestation in a combined total of 61 174 singleton pregnancies, including 1770 (2.9%) that developed PE. Bayes' theorem was used to combine the prior distribution of gestational age at delivery with PE, obtained from maternal characteristics, with various combinations of biomarker multiples of the median (MoM) values to derive patient-specific risks of delivery with PE at < 37 weeks' gestation. The performance of such screening was estimated.
RESULTS: In pregnancies that developed PE, compared to those without PE, the MoM values of UtA-PI and MAP were increased and those of PAPP-A and PlGF were decreased, and the deviation from normal was greater for early than late PE for all four biomarkers. Combined screening by maternal factors, UtA-PI, MAP and PlGF predicted 90% of early PE, 75% of preterm PE and 41% of term PE, at a screen-positive rate of 10%; inclusion of PAPP-A did not improve the performance of screening. The performance of screening depended on the racial origin of the women; on screening by a combination of maternal factors, MAP, UtA-PI and PlGF and using a risk cut-off of 1 in 100 for PE at < 37 weeks in Caucasian women, the screen-positive rate was 10% and detection rates for early, preterm and term PE were 88%, 69% and 40%, respectively. With the same method of screening and risk cut-off in women of Afro-Caribbean racial origin, the screen-positive rate was 34% and detection rates for early, preterm and term PE were 100%, 92% and 75%, respectively.
CONCLUSION: Screening by maternal factors and biomarkers at 11-13 weeks' gestation can identify a high proportion of pregnancies that develop early and preterm PE. © 2018 Crown copyright. Ultrasound in Obstetrics & Gynecology © 2018 ISUOG.
引用
- Tan MY, Syngelaki A, Poon LC, et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol. 2018. PMID: 29896812. doi:10.1002/uog.19112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。